GL Pharm Tech Corp. Logo

GL Pharm Tech Corp.

Develops improved drugs and generics, and licenses proprietary drug formulation technologies.

204840 | KO

Overview

Corporate Details

ISIN(s):
KR7204840003
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 달래내로 46 성남글로벌융합센터 210호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GL Pharm Tech Corp. is a pharmaceutical company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company specializes in creating Incrementally Modified Drugs (IMDs), which are improved versions of existing medications designed to offer benefits such as reduced side effects or modified-release formulations. It provides generic drugs and licenses its proprietary drug formulation and delivery platform technologies to other pharmaceutical firms. The company's core competency lies in developing innovative formulations to enhance the efficacy and patient profile of established therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
Regulatory News Service
불성실공시법인미지정 (지정유예)
Korean 5.6 KB
2025-08-25 00:00
Regulatory News Service
불성실공시법인지정예고 (공시번복)
Korean 4.9 KB
2025-08-14 00:00
M&A Activity
[기재정정]주요사항보고서(회사합병결정)
Korean 96.7 KB
2025-08-14 00:00
M&A Activity
기타주요경영사항 (회사 합병결정 철회)
Korean 7.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-03 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.7 KB
2025-07-03 00:00
M&A Activity
[첨부추가]주요사항보고서(회사합병결정)
Korean 94.9 KB
2025-05-12 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.6 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-26 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.3 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 25.9 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.7 MB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 14.3 KB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 159.7 KB

Automate Your Workflow. Get a real-time feed of all GL Pharm Tech Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GL Pharm Tech Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GL Pharm Tech Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland
NANOFH

Talk to a Data Expert

Have a question? We'll get back to you promptly.